- $2.11bn
- $3.35bn
- $868.76m
- 54
- 28
- 84
- 55
2020 January 26th | C2021 January 31st | C2022 January 30th | 2023 January 29th | 2024 January 28th | |
---|---|---|---|---|---|
Period Length: | 52 W | 53 W | 52 W | 52 W | 52 W |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 548 | 595 | 741 | 757 | 869 |
Cost of Revenue | |||||
Gross Profit | 337 | 356 | 461 | 480 | 389 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 497 | 527 | 597 | 672 | 1,817 |
Operating Profit | 50.8 | 68.2 | 144 | 84.4 | -948 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 44.6 | 63 | 139 | 78.5 | -1,042 |
Provision for Income Taxes | |||||
Net Income After Taxes | 31.8 | 59.5 | 124 | 61.1 | -1,092 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 31.9 | 59.9 | 126 | 61.4 | -1,092 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 31.9 | 59.9 | 126 | 61.4 | -1,092 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.53 | 0.863 | 1.83 | 1.77 | -7.8 |